Treatment of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Systematic Review
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
CONTEXT: Immunosuppressive therapies for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis have greatly advanced patient survival but have turned ANCA-associated vasculitis (AAV) into chronic, relapsing disorders. Long-term treatment and disease-related morbidity are major threats. The last decade has seen a collaborative international effort to determine effective treatment. OBJECTIVE: To analyze the reported evidence on AAV therapy in order to provide physicians with a rational approach for dealing with various clinical scenarios. DATA SOURCES: We searched English-language articles on the medical treatment of AAV published between 1966 and March 2007 using MEDLINE. Articles from the reference lists of the most relevant articles retrieved were also analyzed. STUDY SELECTION: Studies of current available drug treatments or medical interventions for patients with AAV were included. Duplicate publications, case reports, and uncontrolled trials and series including fewer than 10 patients were excluded. DATA SYNTHESIS: We included 2 meta-analyses, 20 randomized controlled prospective trials, and 62 uncontrolled trials with more than 10 patients or observational studies. Outcome measures and treatment protocols were heterogeneous across trials. Cotrimoxazole can be used alone or in combination with corticosteroids to induce and maintain remission in cases of isolated upper respiratory tract involvement. To induce remission, methotrexate plus corticosteroids can be used instead of cyclophosphamide for patients with generalized, non-organ-threatening disease. When methotrexate is used as maintenance therapy, the likelihood of relapse is high and rigorous monitoring is mandatory. Pulse cyclophosphamide with corticosteroids can be used to induce remission in patients with generalized organ-threatening disease. The combination of azathioprine and daily prednisone is effective in maintaining remission. Plasma exchange is at present the best complement to immunosuppressants in advanced renal disease. In Churg-Strauss syndrome, treatment can be started with high doses of corticosteroids, tapering them when the clinical situation improves. In patients with a high risk of death, cyclophosphamide should be introduced. CONCLUSIONS: Although AAV therapies should be tailored to the patient's specific clinical situation, evidence for treatment of several disease states is lacking. There is a need for safer and more effective drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J. W. C., Dadoniené, J., Ekstrand, A., Gaskin, G., Gregorini, G., de Groot, K., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020286 · Cited by 1,348 · cited 4×
“Systemic Vasculitis) study by Jayne et al.(9) Seventy-three patients were randomly assigned to continue cyclo-”
BackgroundMethodInfluentialSelf-citation
Cited by
Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report
Papadopoulos, N. G., Bernstein, J. A., Demoly, P., Dykewicz, M., Fokkens, W., Hellings, P. W., Peters, A. T., Rondon, C., Togias, A., & Cox, L. S. (2015) · Allergy · doi:10.1111/all.12573 · Cited by 182
Metadata
- Authors
- Bosch, X., Guilabert, A., Espinosa, G., & Mirapeix, E.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2007-08-08
- Volume
- 298
- Issue
- 6
- Pages
- 655
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1971736788
- Cited by
- 196
- References
- 1
- FWCI
- 13.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Systematic Review. https://app.cochat.ai/papers/10.1001/jama.298.6.655
- The paper
- Bosch, X., Guilabert, A., Espinosa, G., & Mirapeix, E. (2007). Treatment of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Systematic Review. JAMA. https://doi.org/10.1001/jama.298.6.655
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.